false
0001757499
0001757499
2025-06-20
2025-06-20
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): June 20, 2025
SHUTTLE
PHARMACEUTICALS HOLDINGS, INC.
(Exact
name of registrant as specified in its charter)
| Delaware |
|
001-41488 |
|
82-5089826 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
401
Professional Drive, Suite 260
Gaithersburg,
MD 20879
(Address
of principal executive offices) (Zip Code)
(240)
430-4212
(Registrant’s
telephone number, including area code)
N/A
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common Stock $0.00001 per
share |
|
SHPH |
|
The Nasdaq Stock Market
LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
1.01. Entry into a Material Definitive Agreement.
On
June 20, 2025, Shuttle Pharmaceuticals Holdings, Inc. (the “Company”) entered into a securities purchase agreement with an
accredited investor, for the sale by the Company to the investor, in a private placement, of 21,924 shares of common stock and 1,158,953
pre-funded warrants to purchase shares of common stock, at a purchase price of $3.60 per share or $3.599 per pre-funded warrant. The
private placement closed on June 24, 2025.
The
pre-funded warrants are immediately exercisable, at a nominal exercise price of $0.001, and may be exercised at any time until all of
the pre-funded warrants are exercised in full. The pre-funded warrants may not be exercised to the extent such exercise would result
in the holder beneficially owning more than 4.99% of the Company’s outstanding common stock.
In
connection with the purchase agreement, the Company entered into a registration rights agreement with the investor. Pursuant to the registration
rights agreement, the Company will be required to file a registration statement with the Securities and Exchange Commission (the “SEC”)
to register for resale the shares of common stock, and the shares issuable upon exercise of the pre-funded warrants issued under the
purchase agreement, within 10 days of the closing date, and to have such registration statement declared effective within 90 days of
the closing date (or 120 days if the registration statement is reviewed by the SEC). The Company will be obligated to pay certain liquidated
damages to the investor if the Company fails to file the resale registration statement, or to have such registration statement declared
effective by such dates.
Pursuant
to the purchase agreement, the Company and its directors and executive officers agreed, subject to certain exceptions, not to issue or
sell shares of common stock, or securities convertible into or exercisable for shares of common stock, for a period commencing on the
closing date until the later of (a) sixty days from the closing date or (b) the earlier of (i) 30 days after the effective date of the
resale registration statement to be filed under the registration rights agreement or (ii) 120 days from the closing date.
WestPark
Capital, Inc. (“WestPark”) acted as the placement agent in connection with the private placement pursuant to an engagement
agreement between the Company and WestPark, as amended (as amended, the “Engagement Agreement”). Pursuant to the Engagement
Agreement, the Company paid WestPark a fee of 4% of the gross proceeds received by the Company in the private placement. The Company
also reimbursed certain expenses of WestPark.
In
connection with the foregoing, the Company relied upon the exemption from registration provided by Section 4(a)(2) under the Securities
Act of 1933, as amended, for transactions not involving a public offering.
The
foregoing descriptions of the purchase agreement, pre-funded warrants, and registration rights agreement are subject to, and qualified
in their entirety by, the full text of such documents, which are filed as exhibits to this report and are incorporated herein by reference.
Item
3.02 Unregistered Sales of Equity Securities.
The
disclosure under Item 1.01 above is incorporated herein by reference.
Item
8.01 Other Events.
On
June 20, 2025, the Company issued a press release regarding the pricing of the private placement. A copy of the press release is filed
as an exhibit to this report. On June 24, 2025, the Company issued a press release regrading the closing of the private placement. A
copy of the press release is filed as an exhibit to this report.
Item
9.01 Financial Statements and Exhibits.
| Exhibit
No. |
|
Exhibit
Description |
| 10.1
|
|
Securities Purchase Agreement, dated June 20, 2025 |
| 10.2
|
|
Registration Rights Agreement, dated June 20, 2025 |
| 10.3
|
|
Form of Pre-Funded Warrant |
| 99.1
|
|
Press Release, dated June 20, 2025 |
| 99.2
|
|
Press Release, dated June 24, 2025 |
| 104 |
|
Cover
Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
SHUTTLE
PHARMACEUTICALS HOLDINGS, INC. |
| Dated:
June 25, 2025 |
|
|
| |
By: |
/s/
Christopher Cooper |
| |
Name:
|
Christopher
Cooper |
| |
Title: |
Interim
Chief Executive Officer |
